Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
By week 24 of the study, a reduction in palpable spleen length of at least 50% was reported in more than half of patients who underwent splenomegaly.
Researchers assessed how the reasons that led to discontinuation of ruxolitinib influenced survival in patients with myelofibrosis.
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Researchers assessed patterns of genetic mutations and their prognostic effects in patients with primary and secondary myelofibrosis.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Patients who experienced an iron chelation response had lower transfusion burden and substantial decrease in ferritin values.
The combination of the 2 drugs seems to display synergistic effects.
